Malignant gliomas are the commonest primary malignant tumours of the brain and carry a poor prognosis with current treatment modalities. Chemotherapy is an increasingly important treatment option for these turnouts; however response is limited by the development of drug resistance. A study was undertaken to investigate the feasibility of providing information about tumour chemosensitivity in vitro by culturing glioma tumour cells in a hospital setting and performing chemnosensitivity assays on them using five common chemotherapeutic agents i.e. Cisplatin, Carmustine, Paclitaxel, Temozolomide and Etoposide. It was found that a successful culture was obtained in roughly half the patients (21/47) where culture was attempted, and in those succe...
Background: Although several studies suggest that stromal fibroblasts mediate treatment resistance i...
textabstractSerum-free culture methods for patient-derived primary glioma cultures, selecting for gl...
TRAIL/Apo-2L has shown promise as an anti-glioma drug, based on investigations of TRAIL sensitivity ...
Objective To study the sensitivity of primary human glioma cell to chemotherapeutic agents in vitro ...
Various in-vitro chemosensitivity and resistance assays (CSRAs) have been demonstrated to be helpful...
Cancer treatment is currently empirical. Evidence of genetic, molecular cell pathology and clinical ...
The relative resistance of malignant glioma to chemotherapy makes the identification of new cytotoxi...
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumour. Despite advanc...
The purpose of the study was to analyze the existing methodological approaches to the experimental t...
Gliomas are refractory to chemotherapy because of acquired resistance, which is associated with chan...
Glioblastomas are characterised by remarkably high resistance to chemotherapy. The majority of patie...
With the use of the Human Brain Tumor Stem Cell Assay (HBTSCA) in a cross-resistance study, four ear...
Glioblastoma (GBM) is the most common primary brain malignancy in adults, yet survival outcomes rema...
The purpose of the study was to analyze the existing methodological approaches to the experimental t...
BACKGROUND: Despite the well described heterogeneity in glioblastoma (GBM), treatment is standardize...
Background: Although several studies suggest that stromal fibroblasts mediate treatment resistance i...
textabstractSerum-free culture methods for patient-derived primary glioma cultures, selecting for gl...
TRAIL/Apo-2L has shown promise as an anti-glioma drug, based on investigations of TRAIL sensitivity ...
Objective To study the sensitivity of primary human glioma cell to chemotherapeutic agents in vitro ...
Various in-vitro chemosensitivity and resistance assays (CSRAs) have been demonstrated to be helpful...
Cancer treatment is currently empirical. Evidence of genetic, molecular cell pathology and clinical ...
The relative resistance of malignant glioma to chemotherapy makes the identification of new cytotoxi...
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumour. Despite advanc...
The purpose of the study was to analyze the existing methodological approaches to the experimental t...
Gliomas are refractory to chemotherapy because of acquired resistance, which is associated with chan...
Glioblastomas are characterised by remarkably high resistance to chemotherapy. The majority of patie...
With the use of the Human Brain Tumor Stem Cell Assay (HBTSCA) in a cross-resistance study, four ear...
Glioblastoma (GBM) is the most common primary brain malignancy in adults, yet survival outcomes rema...
The purpose of the study was to analyze the existing methodological approaches to the experimental t...
BACKGROUND: Despite the well described heterogeneity in glioblastoma (GBM), treatment is standardize...
Background: Although several studies suggest that stromal fibroblasts mediate treatment resistance i...
textabstractSerum-free culture methods for patient-derived primary glioma cultures, selecting for gl...
TRAIL/Apo-2L has shown promise as an anti-glioma drug, based on investigations of TRAIL sensitivity ...